title: Low High-Density Lipoprotein and Risk of Myocardial Infarction.
abstract: Low HDL is an independent risk factor for myocardial infarction. This paper reviews our current understanding of HDL, HDL structure and function, HDL subclasses, the relationship of low HDL with myocardial infarction, HDL targeted therapy, and clinical trials and studies. Furthermore potential new agents, such as alirocumab (praluent) and evolocumab (repatha) are discussed.
authors.affiliation: University of California, Riverside, School of Medicine, Riverside, CA, USA. ; Riverside Medical Clinic, Riverside, CA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Ramirez
authors.affiliation: University of California, Riverside, School of Medicine, Riverside, CA, USA. ; Riverside Medical Clinic, Riverside, CA, USA.
authors.forename: P P
authors.initials: PP
authors.lastname: Hu
keywords: AIM-HIGH; Apo; ApoA-I; ApoA-II; Biosynthesis; CETP; HDL; HDL subclass; HDL-C; HP2-THRIVE; LDL; LIPG; ODYSSEY; OSLER; PAF-AH; PCSK; PCSK9; PON1; TRIUMPH; acetylhydrolase; alirocumab; apolipoprotein; atheroprotective; cholesterol; convertase; dyslipidemia; elimination; endothelial lipase gene; evolocumab; heart attack; high density lipoprotein; hyperlipidemia; kexin; low HDL; monoclonal antibody; myocardial infarction; niacin; paraoxonase-1; platelet activating factor; praluent; proprotein; repatha; review; statin; storage; sublisin